Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling

Cancer Cell

Volumn 34, Issue 3, 2018, Pages 379-395.e7

  Forget, Antoine ^a,b   Martignetti, Loredana ^a,c,d,e   Puget, Stéphanie ^f   Calzone, Laurence ^a,c,d,e   Brabetz, Sebastian ^g,h   Picard, Daniel ^h,i,j,p   Montagud, Arnau ^a,c,d,e   Liva, Stéphane ^a,c,d,e   Sta, Alexandre ^a,c,d,e   Dingli, Florent ^a   Arras, Guillaume ^a   Rivera, Jaime ^a   Loew, Damarys ^a   Besnard, Aurore ^k,q   Lacombe, Joëlle ^k,q   Pagès, Mélanie ^k,q   Varlet, Pascale ^k,q   Dufour, Christelle ^l   Yu, Hua ^a,b   Mercier, Audrey L ^a,b   Indersie, Emilie ^a,b   Chivet, Anaïs ^a,b   Leboucher, Sophie ^a,c   Sieber, Laura ^g,h   Beccaria, Kevin ^f   Gombert, Michael ⁱ   Meyer, Frauke D ^h,i,j,p   Qin, Nan ^h,i,j,p   Bartl, Jasmin ^h,i,j,p   Chavez, Lukas ^g,h   Okonechnikov, Konstantin ^g,h   Sharma, Tanvi ^g,h   Thatikonda, Venu ^g,h   Bourdeaut, Franck ^a   Pouponnot, Celio ^a,b   Ramaswamy, Vijay ^m   Korshunov, Andrey ⁿ   Borkhardt, Arndt ⁱ   Reifenberger, Guido ^j   Poullet, Patrick ^a,c,d,e   Taylor, Michael D ^m,o   Kool, Marcel ^g,h   Pfister, Stefan M ^g,h,n   Kawauchi, Daisuke ^g,h   Barillot, Emmanuel ^a,c,d,e   Remke, Marc ^h,i,j,p   Ayrault, Olivier ^a,b   more..

^a PSL RESEARCH UNIVERSITY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT CURIE   (France)

^d INSERM U900   (France)

^e PSL RESEARCH UNIVERSITY   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g Preclinical Program   (Germany)

^h GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

ⁱ UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^j HEINRICH HEINE UNIVERSITY   (Germany)

^k CENTRE HOSPITALIER SAINTE ANNE   (France)

^l INSTITUT GUSTAVE ROUSSY   (France)

^m HOSPITAL FOR SICK CHILDREN   (Canada)

ⁿ UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^o UNIVERSITY OF TORONTO   (Canada)

^p Partner Site   (Germany)

^q UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

medulloblastoma; multi omics; proteomics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 4; PROTEIN P53; RNA BINDING PROTEIN; ERBB4 PROTEIN, HUMAN; ERBB4 PROTEIN, MOUSE; PROTEIN TYROSINE KINASE; PROTEOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA METHYLATION; ENZYME ACTIVITY; GENE IDENTIFICATION; HUMAN; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PHOSPHOPROTEOMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SUBUNIT; RNA METABOLISM; RNA PROCESSING; RNA SEQUENCE; SRC HOMOLOGY DOMAIN; TRANSCRIPTOMICS; TRANSLATION INITIATION; ADOLESCENT; ANIMAL; CARCINOGENESIS; CEREBELLUM; CEREBELLUM TUMOR; CHILD; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; INFANT; MALE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PRESCHOOL CHILD; PROCEDURES; PROTEOMICS; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE;

ADOLESCENT; ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; CEREBELLAR NEOPLASMS; CEREBELLUM; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; MALE; MEDULLOBLASTOMA; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; PROTEOME; PROTEOMICS; RECEPTOR, ERBB-4; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 85052123474     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2018.08.002     Document Type: Article

References (85)

1. Araki, S., Dairiki, R., Nakayama, Y., Murai, A., Miyashita, R., Iwatani, M., Nomura, T., Nakanishi, O., Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing. PLoS One, 10, 2015, e0116929.
2. Archer, T.C., Ehrenberger, T., Mundt, F., Gold, M.P., Krug, K., Mah, C.K., Mahoney, E.L., Daniel, C.J., LeNail, A., Ramamoorthy, D., et al. Proteomics, post-translational modifications, and integrative analyses reveal heterogeneity of molecular mechanisms within medulloblastoma subgroups. Cancer Cell 34 (2018), 396–410 this issue.
3. Bennetzen, M.V., Cox, J., Mann, M., Andersen, J.S., PhosphoSiteAnalyzer: a bioinformatic platform for deciphering phospho proteomes using kinase predictions retrieved from NetworKIN. J. Proteome Res. 11 (2012), 3480–3486.
4. Bian, Y., Ye, M., Wang, C., Cheng, K., Song, C., Dong, M., Pan, Y., Qin, H., Zou, H., Global screening of CK2 kinase substrates by an integrated phosphoproteomics workflow. Sci. Rep., 3, 2013, 3460.
5. Cavalli, F.M.G., Remke, M., Rampasek, L., Peacock, J., Shih, D.J.H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A.S., et al. Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31 (2017), 737–754.e6.
6. Cho, Y.J., Tsherniak, A., Tamayo, P., Santagata, S., Ligon, A., Greulich, H., Berhoukim, R., Amani, V., Goumnerova, L., Eberhart, C.G., et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J. Clin. Oncol. 29 (2011), 1424–1430.
7. Chou, M.F., Schwartz, D., Biological sequence motif discovery using motif-x. Curr. Protoc. Bioinformatics 13 (2011), 15–24.
8. Clifford, S.C., Lusher, M.E., Lindsey, J.C., Langdon, J.A., Gilbertson, R.J., Straughton, D., Ellison, D.W., Wnt/Wingless pathway activation and chromosome 6 loss characterize a distinct molecular sub-group of medulloblastomas associated with a favorable prognosis. Cell Cycle 5 (2006), 2666–2670.
9. Dobin, A., Davis, C.A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., Gingeras, T.R., STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29 (2013), 15–21.
10. Durinck, S., Spellman, P.T., Birney, E., Huber, W., Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. Nat. Protoc. 4 (2009), 1184–1191.
11. Fabregat, A., Sidiropoulos, K., Garapati, P., Gillespie, M., Hausmann, K., Haw, R., Jassal, B., Jupe, S., Korninger, F., McKay, S., et al. The reactome pathway knowledgebase. Nucleic Acids Res. 44 (2016), D481–D487.
12. Fan, J., Salathia, N., Liu, R., Kaeser, G.E., Yung, Y.C., Herman, J.L., Kaper, F., Fan, J.B., Zhang, K., Chun, J., et al. Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis. Nat. Methods 13 (2016), 241–244.
13. Geiger, T., Cox, J., Ostasiewicz, P., Wisniewski, J.R., Mann, M., Super-SILAC mix for quantitative proteomics of human tumor tissue. Nat. Methods 7 (2010), 383–385.
14. Geiger, T., Wisniewski, J.R., Cox, J., Zanivan, S., Kruger, M., Ishihama, Y., Mann, M., Use of stable isotope labeling by amino acids in cell culture as a spike-in standard in quantitative proteomics. Nat. Protoc. 6 (2011), 147–157.
15. Gilbertson, R.J., Clifford, S.C., MacMeekin, W., Meekin, W., Wright, C., Perry, R.H., Kelly, P., Pearson, A.D., Lunec, J., Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. Cancer Res. 58 (1998), 3932–3941.
16. Gilbertson, R.J., Perry, R.H., Kelly, P.J., Pearson, A.D., Lunec, J., Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res. 57 (1997), 3272–3280.
17. Gottardo, N.G., Hansford, J.R., McGlade, J.P., Alvaro, F., Ashley, D.M., Bailey, S., Baker, D.L., Bourdeaut, F., Cho, Y.J., Clay, M., et al. Medulloblastoma down under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 127 (2014), 189–201.
18. Greenbaum, D., Colangelo, C., Williams, K., Gerstein, M., Comparing protein abundance and mRNA expression levels on a genomic scale. Genome Biol., 4, 2003, 117.
19. Guo, J., Hao, J., Jiang, H., Jin, J., Wu, H., Jin, Z., Li, Z., Proteasome activator subunit 3 promotes pancreatic cancer growth via c-Myc-glycolysis signaling axis. Cancer Lett. 386 (2017), 161–167.
20. Horn, H., Schoof, E.M., Kim, J., Robin, X., Miller, M.L., Diella, F., Palma, A., Cesareni, G., Jensen, L.J., Linding, R., KinomeXplorer: an integrated platform for kinome biology studies. Nat. Methods 11 (2014), 603–604.
21. Hovestadt, V., Jones, D.T., Picelli, S., Wang, W., Kool, M., Northcott, P.A., Sultan, M., Stachurski, K., Ryzhova, M., Warnatz, H.J., et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature 510 (2014), 537–541.
22. Hovestadt, V., Remke, M., Kool, M., Pietsch, T., Northcott, P.A., Fischer, R., Cavalli, F.M., Ramaswamy, V., Zapatka, M., Reifenberger, G., et al. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol. 125 (2013), 913–916.
23. Irby, R.B., Mao, W., Coppola, D., Kang, J., Loubeau, J.M., Trudeau, W., Karl, R., Fujita, D.J., Jove, R., Yeatman, T.J., Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. 21 (1999), 187–190.
24. Ishizawar, R., Parsons, S.J., c-Src and cooperating partners in human cancer. Cancer Cell 6 (2004), 209–214.
25. Karaki, S., Andrieu, C., Ziouziou, H., Rocchi, P., The eukaryotic translation initiation factor 4E (eIF4E) as a therapeutic target for cancer. Adv. Protein Chem. Struct. Biol. 101 (2015), 1–26.
26. Kawauchi, D., Ogg, R.J., Liu, L., Shih, D.J.H., Finkelstein, D., Murphy, B.L., Rehg, J.E., Korshunov, A., Calabrese, C., Zindy, F., et al. Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. Oncogene 36 (2017), 5231–5242.
27. Kool, M., Jones, D.T., Jäger, N., Northcott, P.A., Pugh, T.J., Hovestadt, V., Piro, R.M., Esparza, L.A., Markant, S.L., Remke, M., et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 25 (2014), 393–405.
28. Kool, M., Korshunov, A., Remke, M., Jones, D.T., Schlanstein, M., Northcott, P.A., Cho, Y.J., Koster, J., Schouten-van Meeteren, A., van Vuurden, D., et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 123 (2012), 473–484.
29. Kool, M., Koster, J., Bunt, J., Hasselt, N.E., Lakeman, A., van Sluis, P., Troost, D., Meeteren, N.S., Caron, H.N., Cloos, J., et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One, 3, 2008, e3088.
30. Lan, T., Wang, H., Zhang, Z., Zhang, M., Qu, Y., Zhao, Z., Fan, X., Zhan, Q., Song, Y., Yu, C., Downregulation of β-arrestin 1 suppresses glioblastoma cell malignant progression vis inhibition of Src signaling. Exp. Cell Res. 357 (2017), 51–58.
31. Langmead, B., Salzberg, S.L., Fast gapped-read alignment with Bowtie 2. Nat. Methods 9 (2012), 357–359.
32. Laplante, M., Sabatini, D.M., MTOR signaling in growth control and disease. Cell 149 (2012), 274–293.
33. Lappano, R., Maggiolini, M., G protein-coupled receptors: novel targets for drug discovery in cancer. Nat. Rev. Drug Discov. 10 (2011), 47–60.
34. Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E., Storey, J.D., The SVA package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 28 (2012), 882–883.
35. Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J.P., Tamayo, P., The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1 (2015), 417–425.
36. Lin, C.Y., Erkek, S., Tong, Y., Yin, L., Federation, A.J., Zapatka, M., Haldipur, P., Kawauchi, D., Risch, T., Warnatz, H.J., Worst, B.C., Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature 530 (2016), 57–62.
37. Louis, D.N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W.K., Ohgaki, H., Wiestler, O.D., Kleihues, P., Ellison, D.W., The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131 (2016), 803–820.
38. Martignetti, L., Calzone, L., Bonnet, E., Barillot, E., Zinovyev, A., ROMA: representation and quantification of module activity from target expression data. Front. Genet., 7, 2016, 18.
39. Merico, D., Isserlin, R., Stueker, O., Emili, A., Bader, G.D., Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PLoS One, 5, 2010, e13984.
40. Mertins, P., Mani, D.R., Ruggles, K.V., Gillette, M.A., Clauser, K.R., Wang, P., Wang, X., Qiao, J.W., Cao, S., Petralia, F., et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534 (2016), 55–62.
41. Milde, T., Lodrini, M., Savelyeva, L., Korshunov, A., Kool, M., Brueckner, L.M., Antunes, A.S., Oehme, I., Pekrun, A., Pfister, S.M., et al. HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. J. Neurooncol. 110 (2012), 335–348.
42. Mootha, V.K., Lindgren, C.M., Eriksson, K.F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34 (2003), 267–273.
43. Nagaraj, N., Wisniewski, J.R., Geiger, T., Cox, J., Kircher, M., Kelso, J., Pääbo, S., Mann, M., Deep proteome and transcriptome mapping of a human cancer cell line. Mol. Syst. Biol., 7, 2011, 548.
44. Northcott, P.A., Buchhalter, I., Morrissy, A.S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V.A., et al. The whole-genome landscape of medulloblastoma subtypes. Nature 547 (2017), 311–317.
45. Northcott, P.A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C.G., Mack, S., Bouffet, E., Clifford, S.C., Hawkins, C.E., French, P., et al. Medulloblastoma comprises four distinct molecular variants. J. Clin. Oncol. 29 (2011), 1408–1414.
46. Northcott, P.A., Lee, C., Zichner, T., Stütz, A.M., Erkek, S., Kawauchi, D., Shih, D.J., Hovestadt, V., Zapatka, M., Sturm, D., et al. Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature 511 (2014), 428–434.
47. Northcott, P.A., Shih, D.J., Remke, M., Cho, Y.J., Kool, M., Hawkins, C., Eberhart, C.G., Dubuc, A., Guettouche, T., Cardentey, Y., et al. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 123 (2012), 615–626.
48. Obara, Y., Labudda, K., Dillon, T.J., Stork, P.J., PKA phosphorylation of Src mediates Rap1 activation in NGF and cAMP signaling in PC12 cells. J. Cell Sci. 117 (2004), 6085–6094.
49. Pei, Y., Moore, C.E., Wang, J., Tewari, A.K., Eroshkin, A., Cho, Y.J., Witt, H., Korshunov, A., Read, T.A., Sun, J.L., et al. An animal model of MYC-driven medulloblastoma. Cancer Cell 21 (2012), 155–167.
50. Pfister, S., Remke, M., Benner, A., Mendrzyk, F., Toedt, G., Felsberg, J., Wittmann, A., Devens, F., Gerber, N.U., Joos, S., et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J. Clin. Oncol. 27 (2009), 1627–1636.
51. Poullet, P., Carpentier, S., Barillot, E., myProMS, a web server for management and validation of mass spectrometry-based proteomic data. Proteomics 7 (2007), 2553–2556.
52. Ramaswamy, V., Remke, M., Bouffet, E., Bailey, S., Clifford, S.C., Doz, F., Kool, M., Dufour, C., Vassal, G., Milde, T., et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 131 (2016), 821–831.
53. Remke, M., Hielscher, T., Korshunov, A., Northcott, P.A., Bender, S., Kool, M., Westermann, F., Benner, A., Cin, H., Ryzhova, M., et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J. Clin. Oncol. 29 (2011), 3852–3861.
54. Remke, M., Hielscher, T., Northcott, P.A., Witt, H., Ryzhova, M., Wittmann, A., Benner, A., von Deimling, A., Scheurlen, W., Perry, A., et al. Adult medulloblastoma comprises three major molecular variants. J. Clin. Oncol. 29 (2011), 2717–2723.
55. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 43, 2015, e47.
56. Robinson, G., Parker, M., Kranenburg, T.A., Lu, C., Chen, X., Ding, L., Phoenix, T.N., Hedlund, E., Wei, L., Zhu, X., et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 488 (2012), 43–48.
57. Sato, Y., Kasai, T., Nakagawa, S., Tanabe, K., Watanabe, T., Kawakami, K., Takahashi, Y., Stable integration and conditional expression of electroporated transgenes in chicken embryos. Dev. Biol. 305 (2007), 616–624.
58. Schaefer, C.F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T., Buetow, K.H., PID: the pathway interaction database. Nucleic Acids Res. 37 (2009), D674–D679.
59. Schwalbe, E.C., Lindsey, J.C., Nakjang, S., Crosier, S., Smith, A.J., Hicks, D., Rafiee, G., Hill, R.M., Iliasova, A., Stone, T., et al. Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. Lancet Oncol. 18 (2017), 958–971.
60. Schwalbe, E.C., Williamson, D., Lindsey, J.C., Hamilton, D., Ryan, S.L., Megahed, H., Garami, M., Hauser, P., Dembowska-Baginska, B., Perek, D., et al. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathol. 125 (2013), 359–371.
61. Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., Selbach, M., Global quantification of mammalian gene expression control. Nature 473 (2011), 337–342.
62. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B., Ideker, T., Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13 (2003), 2498–2504.
63. Shih, D.J., Northcott, P.A., Remke, M., Korshunov, A., Ramaswamy, V., Kool, M., Luu, B., Yao, Y., Wang, X., Dubuc, A.M., et al. Cytogenetic prognostication within medulloblastoma subgroups. J. Clin. Oncol. 32 (2014), 886–896.
64. Shukla, A.K., Xiao, K., Lefkowitz, R.J., Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem. Sci. 36 (2011), 457–469.
65. Sturm, D., Orr, B.A., Toprak, U.H., Hovestadt, V., Jones, D.T.W., Capper, D., Sill, M., Buchhalter, I., Northcott, P.A., Leis, I., et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 164 (2016), 1060–1072.
66. Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102 (2005), 15545–15550.
67. Sugimura, M., Kobayashi, K., Sagae, S., Nishioka, Y., Ishioka, S., Terasawa, K., Tokino, T., Kudo, R., Mutation of the SRC gene in endometrial carcinoma. Jpn. J. Cancer Res. 91 (2000), 395–398.
68. Szklarczyk, D., Morris, J.H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M., Santos, A., Doncheva, N.T., Roth, A., Bork, P., et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res., 45, 2017 D362–DD368.
69. Taus, T., Köcher, T., Pichler, P., Paschke, C., Schmidt, A., Henrich, C., Mechtler, K., Universal and confident phosphorylation site localization using phosphoRS. J. Proteome Res. 10 (2011), 5354–5362.
70. Taylor, M.D., Northcott, P.A., Korshunov, A., Remke, M., Cho, Y.J., Clifford, S.C., Eberhart, C.G., Parsons, D.W., Rutkowski, S., Gajjar, A., et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 123 (2012), 465–472.
71. Thompson, M.C., Fuller, C., Hogg, T.L., Dalton, J., Finkelstein, D., Lau, C.C., Chintagumpala, M., Adesina, A., Ashley, D.M., Kellie, S.J., et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J. Clin. Oncol. 24 (2006), 1924–1931.
72. Thoreen, C.C., The molecular basis of mTORC1-regulated translation. Biochem. Soc. Trans. 45 (2017), 213–221.
73. Truitt, M.L., Ruggero, D., New frontiers in translational control of the cancer genome. Nat. Rev. Cancer, 17, 2017, 332.
74. Vizcaino, J.A., Csordas, A., Del-Toro, N., Dianes, J.A., Griss, J., Lavidas, I., Mayer, G., Perez-Riverol, Y., Reisinger, F., Ternent, T., et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res., 44, 2016, 11033.
75. Wallace, D.C., Mitochondria and cancer. Nat. Rev. Cancer 12 (2012), 685–698.
76. Wang, B., Mezlini, A.M., Demir, F., Fiume, M., Tu, Z., Brudno, M., Haibe-Kains, B., Goldenberg, A., Similarity network fusion for aggregating data types on a genomic scale. Nat. Methods 11 (2014), 333–337.
77. Wang, Z., Transactivation of epidermal growth factor receptor by G protein-coupled receptors: recent progress, challenges and future research. Int. J. Mol. Sci., 17, 2016, 95.
78. Wefers, A.K., Warmuth-Metz, M., Pöschl, J., von Bueren, A.O., Monoranu, C.M., Seelos, K., Peraud, A., Tonn, J.C., Koch, A., Pietsch, T., et al. Subgroup-specific localization of human medulloblastoma based on pre-operative MRI. Acta Neuropathol. 127 (2014), 931–933.
79. Yarden, Y., Sliwkowski, M.X., Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2 (2001), 127–137.
80. Zaiss, D.M., Standera, S., Holzhütter, H., Kloetzel, P., Sijts, A.J., The proteasome inhibitor PI31 competes with PA28 for binding to 20S proteasomes. FEBS Lett. 457 (1999), 333–338.
81. Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M.C., Zimmerman, L.J., Shaddox, K.F., Kim, S., et al. Proteogenomic characterization of human colon and rectal cancer. Nature 513 (2014), 382–387.
82. Zhang, H., Liu, T., Zhang, Z., Payne, S.H., Zhang, B., McDermott, J.E., Zhou, J.Y., Petyuk, V.A., Chen, L., Ray, D., et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell 166 (2016), 755–765.
83. Zhang, S.Q., Yang, W., Kontaridis, M.I., Bivona, T.G., Wen, G., Araki, T., Luo, J., Thompson, J.A., Schraven, B.L., Philips, M.R., et al. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell 13 (2004), 341–355.
84. Zomerman, W.W., Plasschaert, S.L.A., Conroy, S., Scherpen, F.J., Meeuwsen-de Boer, T.G.J., Lourens, H.J., Guerrero Llobet, S., Smit, M.J., Slagter-Menkema, L., Seitz, A., et al. Identification of two protein-signaling states delineating transcriptionally heterogeneous human medulloblastoma. Cell Rep. 22 (2018), 3206–3216.
85. Zuckermann, M., Hovestadt, V., Knobbe-Thomsen, C.B., Zapatka, M., Northcott, P.A., Schramm, K., Belic, J., Jones, D.T., Tschida, B., Moriarity, B., et al. Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nat. Commun., 6, 2015, 7391.